Bellerophon Therapeutics Stock Forecast, Price & News

Bellerophon Therapeutics (NASDAQ:BLPH) Frequently Asked Questions

Is Bellerophon Therapeutics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Bellerophon Therapeutics stock.
View analyst ratings for Bellerophon Therapeutics or view top-rated stocks.

How has Bellerophon Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Bellerophon Therapeutics' stock was trading at $6.29 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BLPH stock has decreased by 57.9% and is now trading at $2.65.
View which stocks have been most impacted by COVID-19.

When is Bellerophon Therapeutics' next earnings date?

Bellerophon Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Bellerophon Therapeutics.

How were Bellerophon Therapeutics' earnings last quarter?

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) posted its quarterly earnings results on Monday, November, 15th. The biotechnology company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.14.
View Bellerophon Therapeutics' earnings history.

When did Bellerophon Therapeutics' stock split? How did Bellerophon Therapeutics' stock split work?

Bellerophon Therapeutics shares reverse split on Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 7th 2020. An investor that had 100 shares of Bellerophon Therapeutics stock prior to the reverse split would have 7 shares after the split.

Who are Bellerophon Therapeutics' key executives?

Bellerophon Therapeutics' management team includes the following people:

• Peter Fernandes, Chief Executive, Regulatory & Safety Officer
• Parag Suresh Shah, Vice President-Business Operations
• Nicholas Laccona, Chief Financial & Accounting Officer
• Edwin L. Parsley, Chief Medical Officer
• Martin Dekker, Vice President-Engineering & Manufacturing

Who are some of Bellerophon Therapeutics' key competitors?

Some companies that are related to Bellerophon Therapeutics include Angion Biomedica (ANGN), Eyenovia (EYEN), SELLAS Life Sciences Group (SLS), Purple Biotech (PPBT), Biofrontera (BFRA), GT Biopharma (GTBP), PhaseBio Pharmaceuticals (PHAS), Orphazyme A/S (ORPH), Petra Acquisition (PAIC), Anixa Biosciences (ANIX), Hepion Pharmaceuticals (HEPA), Eton Pharmaceuticals (ETON), Lipocine (LPCN), Oncolytics Biotech (ONCY) and NeuBase Therapeutics (NBSE).
View all of BLPH's competitors.

What other stocks do shareholders of Bellerophon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Pfizer (PFE), Verastem (VSTM), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX) and Dynavax Technologies (DVAX).

When did Bellerophon Therapeutics IPO?

(BLPH) raised $60 million in an IPO on Friday, February 13th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and Cowen and Company acted as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

What is Bellerophon Therapeutics' stock symbol?

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

Who are Bellerophon Therapeutics' major shareholders?

Bellerophon Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.12%), BlackRock Inc. (1.27%) and Telemetry Investments L.L.C. (0.90%). Company insiders that own Bellerophon Therapeutics stock include New Mountain Investments Ii, L and Wassim Fares.
View institutional ownership trends for Bellerophon Therapeutics.

Which institutional investors are selling Bellerophon Therapeutics stock?

BLPH stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Telemetry Investments L.L.C..
View insider buying and selling activity for Bellerophon Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Bellerophon Therapeutics stock?

BLPH stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc..
View insider buying and selling activity for Bellerophon Therapeutics or or view top insider-buying stocks.

How do I buy shares of Bellerophon Therapeutics?

Shares of BLPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bellerophon Therapeutics' stock price today?

One share of BLPH stock can currently be purchased for approximately $2.65.

How much money does Bellerophon Therapeutics make?

Bellerophon Therapeutics has a market capitalization of $25.20 million. The biotechnology company earns $-24.73 million in net income (profit) each year or ($2.27) on an earnings per share basis.

How many employees does Bellerophon Therapeutics have?

Bellerophon Therapeutics employs 21 workers across the globe.

What is Bellerophon Therapeutics' official website?

The official website for Bellerophon Therapeutics is www.bellerophon.com.

Where are Bellerophon Therapeutics' headquarters?

Bellerophon Therapeutics is headquartered at 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059.

How can I contact Bellerophon Therapeutics?

Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The biotechnology company can be reached via phone at (908) 574-4770 or via email at [email protected].